Clincosm LogoSign in Get a demo

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Sponsor
Ascletis Pharmaceuticals Co., Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT03430830
Collaborator
(none)
12
Enrollment
1
Location
6
Arms
2.8
Actual Duration (Months)
4.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of ASC16 after 3-single dose(50mg、100mg、200mg) or fixed continuous dose(200mg) in healthy volunteers.

Condition or Disease Intervention/Treatment Phase
  • Drug: Ravidasvir 50mg
  • Drug: Ravidasvir 200mg
 Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
12 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Randomized, Open, Three-dose (100 mg, 200 mg and 300 mg) Duplicate Bifunctional Crossover and Fixed 200mg Continuous Dose Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers
Actual Study Start Date :
Jan 15, 2018
Actual Primary Completion Date :
Apr 9, 2018
Actual Study Completion Date :
Apr 9, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: GROUP 1

1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 19th to 25th day： Ravidasvir 200mg administered orally once daily.

Drug: Ravidasvir 50mg
50mg, Tablet
Other Names:
  • ASC16

    • Drug: Ravidasvir 200mg
    200mg, Tablet
    Other Names:
  • ASC16

    		•
    Experimental: GROUP 2

    1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.

    Drug: Ravidasvir 50mg
    50mg, Tablet
    Other Names:
  • ASC16

    • Drug: Ravidasvir 200mg
    200mg, Tablet
    Other Names:
  • ASC16

    		•
    Experimental: GROUP 3

    1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.

    Drug: Ravidasvir 50mg
    50mg, Tablet
    Other Names:
  • ASC16

    • Drug: Ravidasvir 200mg
    200mg, Tablet
    Other Names:
  • ASC16

    		•
    Experimental: GROUP 4

    1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: Ravidasvir 200mg administered orally once daily; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.

    Drug: Ravidasvir 50mg
    50mg, Tablet
    Other Names:
  • ASC16

    • Drug: Ravidasvir 200mg
    200mg, Tablet
    Other Names:
  • ASC16

    		•
    Experimental: GROUP 5

    1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.

    Drug: Ravidasvir 50mg
    50mg, Tablet
    Other Names:
  • ASC16

    • Drug: Ravidasvir 200mg
    200mg, Tablet
    Other Names:
  • ASC16

    		•
    Experimental: GROUP 6

    1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.

    Drug: Ravidasvir 50mg
    50mg, Tablet
    Other Names:
  • ASC16

    • Drug: Ravidasvir 200mg
    200mg, Tablet
    Other Names:
  • ASC16

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Peak plasma concentration (Cmax) [27 days]

      Pharmacokinetics (blood draws, pre- and post-dose)

    2. Area under the plasma concentration versus time curve (AUC) [27 days]

      Pharmacokinetics (blood draws, pre- and post-dose)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Age between 18-45 years old;

    • Male body weight not less than 50kg; Female body weight not less than 45kg; BMI in the range of 19~24kg/m2

    • Healthy men or women based on history, physical examination, laboratory examination and ECG.

    • no plan of pregnancy in at least six months, and willing to take effective measures to prevent contraception from the first time when the drug is administered till the last time the drug is administered within 30 days.

    • Female has negative pregnancy tests at the screening stage.

    • Voluntary to sign the informed consent.

    Exclusion Criteria:

    • Have medical history, or has disease, such as cardiovascular system, respiratory system, endocrine and metabolic system, urinary system, digestive system, blood system, nerve system disease or psychiatric disease and acute or chronic infectious diseases and malignant tumors.

    • Has a history of drug or food allergy.

    • Positive hepatitis A antibody，positive hepatitis B surface antigen， positive hepatitis C antibody，syphilis antibody or HIV antibody at screening.

    • Laboratory tests out of normal range and judged by the investigators as clinically significant.

    • Had gastrointestinal surgery, vagotomy, intestinal resection or any possible interference with gastrointestinal peristalsis, pH or absorbed by surgery.

    • Pregnant, lactating women and people who unwilling to take effective measures to prevent contraception.

    • People who consumed pomelo, apple or orange and foods or drinks containing their extracted ingredients within 3 days of taking the drug.

    • Any prescription or over-the-counter medications, herbs, and vitamins are required to be taken prior to or within the first month of taking the drug.

    • Selected within the first 6 months of smoking, alcohol, drug abuse or history of drug abuse.

    • Selected within the first 3 months had blood loss or blood donation of 200ml.

    • Participate in other clinical trials within the first 3 months of the study and received other study drug treatment.

    • In addition to the above, the investigators judged not suitable for participating in this clinical trial.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 First Hospital of Zhejiang Province Hangzhou Zhejiang China 310003

    Sponsors and Collaborators

    • Ascletis Pharmaceuticals Co., Ltd.

    Investigators

    • Study Director: Yahong Chen, Master, Ascletis Pharmaceuticals Co., Ltd.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ascletis Pharmaceuticals Co., Ltd.
    ClinicalTrials.gov Identifier:
    NCT03430830
    Other Study ID Numbers:
    • ASC-ASC16-I-CTP-03
    First Posted:
    Feb 13, 2018
    Last Update Posted:
    Jun 29, 2018
    Last Verified:
    Jan 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Hepatitis C
    Hepatitis C, Chronic

    Study Results

    No Results Posted as of Jun 29, 2018